BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: von Brunn A, Ciesek S, von Brunn B, Carbajo-Lozoya J. Genetic deficiency and polymorphisms of cyclophilin A reveal its essential role for Human Coronavirus 229E replication. Curr Opin Virol 2015;14:56-61. [PMID: 26318518 DOI: 10.1016/j.coviro.2015.08.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 LoPresti M, Beck DB, Duggal P, Cummings DAT, Solomon BD. The Role of Host Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic Review of Human Literature. medRxiv 2020:2020. [PMID: 32511629 DOI: 10.1101/2020.05.30.20117788] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 von Hahn T, Ciesek S. Cyclophilin polymorphism and virus infection. Curr Opin Virol 2015;14:47-9. [PMID: 26281011 DOI: 10.1016/j.coviro.2015.07.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
3 LoPresti M, Beck DB, Duggal P, Cummings DAT, Solomon BD. The Role of Host Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic Review of Human Literature. Am J Hum Genet 2020;107:381-402. [PMID: 32814065 DOI: 10.1016/j.ajhg.2020.08.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
4 de Wilde AH, Pham U, Posthuma CC, Snijder EJ. Cyclophilins and cyclophilin inhibitors in nidovirus replication. Virology 2018;522:46-55. [PMID: 30014857 DOI: 10.1016/j.virol.2018.06.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
5 Prasad K, Ahamad S, Kanipakam H, Gupta D, Kumar V. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine. ACS Chem Neurosci 2021;12:930-44. [PMID: 33606519 DOI: 10.1021/acschemneuro.1c00019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Ma-Lauer Y, Zheng Y, Malešević M, von Brunn B, Fischer G, von Brunn A. Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication. Antiviral Res 2020;173:104620. [PMID: 31634494 DOI: 10.1016/j.antiviral.2019.104620] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
7 de Wilde AH, Zevenhoven-Dobbe JC, Beugeling C, Chatterji U, de Jong D, Gallay P, Szuhai K, Posthuma CC, Snijder EJ. Coronaviruses and arteriviruses display striking differences in their cyclophilin A-dependence during replication in cell culture. Virology 2018;517:148-56. [PMID: 29249267 DOI: 10.1016/j.virol.2017.11.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
8 Dittmar M, Lee JS, Whig K, Segrist E, Li M, Kamalia B, Castellana L, Ayyanathan K, Cardenas-Diaz FL, Morrisey EE, Truitt R, Yang W, Jurado K, Samby K, Ramage H, Schultz DC, Cherry S. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. Cell Rep 2021;35:108959. [PMID: 33811811 DOI: 10.1016/j.celrep.2021.108959] [Cited by in Crossref: 27] [Cited by in F6Publishing: 38] [Article Influence: 27.0] [Reference Citation Analysis]
9 Ovsyannikova IG, Haralambieva IH, Crooke SN, Poland GA, Kennedy RB. The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. Immunol Rev 2020;296:205-19. [PMID: 32658335 DOI: 10.1111/imr.12897] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 28.5] [Reference Citation Analysis]
10 Evans JP, Liu SL. Role of host factors in SARS-CoV-2 entry. J Biol Chem 2021;297:100847. [PMID: 34058196 DOI: 10.1016/j.jbc.2021.100847] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
11 [DOI: 10.1101/2020.06.19.161042] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
12 Softic L, Brillet R, Berry F, Ahnou N, Nevers Q, Morin-Dewaele M, Hamadat S, Bruscella P, Fourati S, Pawlotsky JM, Ahmed-Belkacem A. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025). Antimicrob Agents Chemother 2020;64:e00876-20. [PMID: 32376613 DOI: 10.1128/AAC.00876-20] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
13 Redzic JS, Lee E, Born A, Issaian A, Henen MA, Nichols PJ, Blue A, Hansen KC, D'Alessandro A, Vögeli B, Eisenmesser EZ. The Inherent Dynamics and Interaction Sites of the SARS-CoV-2 Nucleocapsid N-Terminal Region. J Mol Biol 2021;433:167108. [PMID: 34161778 DOI: 10.1016/j.jmb.2021.167108] [Reference Citation Analysis]
14 Pawlotsky JM. COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir. Clin Infect Dis 2020;71:2191-4. [PMID: 32409832 DOI: 10.1093/cid/ciaa587] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
15 Poulsen NN, von Brunn A, Hornum M, Blomberg Jensen M. Cyclosporine and COVID-19: Risk or favorable? Am J Transplant 2020;20:2975-82. [PMID: 32777170 DOI: 10.1111/ajt.16250] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
16 de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Host Factors in Coronavirus Replication. Curr Top Microbiol Immunol. 2018;419:1-42. [PMID: 28643204 DOI: 10.1007/82_2017_25] [Cited by in Crossref: 106] [Cited by in F6Publishing: 144] [Article Influence: 35.3] [Reference Citation Analysis]
17 de Wilde AH, Boomaars-van der Zanden AL, de Jong AWM, Bárcena M, Snijder EJ, Posthuma CC. Adaptive Mutations in Replicase Transmembrane Subunits Can Counteract Inhibition of Equine Arteritis Virus RNA Synthesis by Cyclophilin Inhibitors. J Virol 2019;93:e00490-19. [PMID: 31243130 DOI: 10.1128/JVI.00490-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Farhat Ullah M, Ali Y, Ramzan Khan M, Ullah Khan I, Yan B, Ijaz Khan M, Malik MY. A review of COVID-19: Treatment Strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease. Saudi J Biol Sci 2021. [PMID: 34658640 DOI: 10.1016/j.sjbs.2021.10.020] [Reference Citation Analysis]
19 Tanaka Y, Sato Y, Sasaki T. Feline coronavirus replication is affected by both cyclophilin A and cyclophilin B. J Gen Virol 2017;98:190-200. [PMID: 27902373 DOI: 10.1099/jgv.0.000663] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
20 Liu C, von Brunn A, Zhu D. Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19. Med Drug Discov 2020;7:100056. [PMID: 32835213 DOI: 10.1016/j.medidd.2020.100056] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
21 Germani F, Wäscher S, Biller-Andorno N. A CRISPR response to pandemics?: Exploring the ethics of genetically engineering the human immune system. EMBO Rep 2021;22:e52319. [PMID: 33615649 DOI: 10.15252/embr.202052319] [Cited by in F6Publishing: 1] [Reference Citation Analysis]